Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.

CEO

Lars Fruergaard Jørgensen

CEOLars Fruergaard Jørgensen

Employees

76,302

Employees76,302

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1931

Founded1931

Employees

76,302

Employees76,302

NVO Key Statistics

Market cap

307.88B

Market cap307.88B

Price-Earnings ratio

20.47

Price-Earnings ratio20.47

Dividend yield

1.71%

Dividend yield1.71%

Average volume

8.49M

Average volume8.49M

High today

$70.15

High today$70.15

Low today

$68.58

Low today$68.58

Open price

$69.22

Open price$69.22

Volume

4.05M

Volume4.05M

52 Week high

$143.69

52 Week high$143.69

52 Week low

$57.00

52 Week low$57.00

NVO News

TipRanks 3d

Novo Nordisk’s Diabetes Study: Promising Results for Cagrilintide and Semaglutide Combo

Novo Nordisk ((DE:NOVA)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% of...

TipRanks 3d

Novo Nordisk’s CagriSema Study: A Potential Game-Changer in Obesity Treatment

Novo Nordisk ((DE:NOVA)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% of...

Seeking Alpha 5d

How mazdutide compares against weight loss therapies from Novo Nordisk, Lilly

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon receptor (GCP) for obesity, observers are...

Analyst ratings

63%

of 32 ratings

Buy

62.5%

Hold

28.1%

Sell

9.4%